Clinical outcomes using a platelet function-guided approach for secondary prevention in patients with ischemic stroke or transient ischemic attack

Stroke

Volumn 43, Issue 9, 2012, Pages 2376-2381

  Depta, Jeremiah P ^a   Fowler, Jeffrey ^b   Novak, Eric ^a   Katzan, Irene ^b   Bakdash, Suzanne ^b   Kottke Marchant, Kandice ^b   Bhatt, Deepak L ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

aspirin; clopidogrel; ischemic stroke; nonresponse; platelet function testing; resistance; transient ischemic attack

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CLOPIDOGREL;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUNCTION TEST; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE;

ADENOSINE DIPHOSPHATE; AGED; ARACHIDONIC ACID; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROPORTIONAL HAZARDS MODELS; SECONDARY PREVENTION; STROKE; SURVIVAL ANALYSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84865608720     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.655084     Document Type: Article

References (26)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics\-2012 update: a report from the American Heart Association. Circulation. 2012;125:188-197.
2. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack. Stroke. 2011;42:227-276.
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myo-cardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
4. Greer DM. Aspirin and antiplatelet agent resistance: implications for prevention of secondary stroke. CNS Drugs. 2010;24:1027-1040.
5. Fukuoka T, Furuya D, Takeda H, Dembo T, Nagoya H, Kato Y, et al. Evaluation of clopidogrel resistance in ischemic stroke patients. Intern Med. 2011;50:31-35.
6. Fong J, Cheng-Ching E, Hussain MS, Katzan I, Gupta R. Predictors of biochemical aspirin and clopidogrel resistance in patients with ischemic stroke. J Stroke Cerebrovasc Dis. 2011;20:227-230.
7. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res. 1993;71:397-403.
8. Schwammenthal Y, Tsabari R, Shenkman B, Schwartz R, Matetzky S, Lubetsky A, et al. Aspirin responsiveness in acute brain ischaemia: association with stroke severity and clinical outcome. Cerebrovasc Dis. 2008;25:355-361.
9. Ozben S, Ozben B, Tanrikulu AM, Ozer F, Ozben T. Aspirin resistance in patients with acute ischemic stroke. J Neurol. 2011;258:1979-1986.
10. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56: 919-933.
11. Selim MH, Molina CA. Platelet function assays in stroke management: more study is needed. Stroke. 2010;41:2396-2397.
12. Eikelboom JW, Emery J, Hankey GJ. The use of platelet function assays may help to determine appropriate antiplatelet treatment options in a patient with recurrent stroke on baby aspirin: against. Stroke. 2010;41: 2398-2399.
13. Depta JP, Bhatt DL. Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance. Am J Cardiovasc Drugs. 2008;8:91-112.
14. Seok JI, Joo IS, Yoon JH, Choi YJ, Lee PH, Huh K, et al. Can aspirin resistance be clinically predicted in stroke patients? Clin Neurol Neu-rosurg. 2008;110:110-116.
15. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1-13.
16. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367: 1665-1673.
17. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329-1339.
18. Johnson ES, Lanes SF, Wentworth CE, Satterfield MH, Abebe BL, Dicker LW. A metaregression analysis of the dose-response effect of aspirin on stroke. Arch Intern Med. 1999;159:1248-1253.
19. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54:1044-1054.
20. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. N Engl J Med. 1991;325:1261-1266.
21. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238-1251.
22. Grau AJ, Reiners S, Lichy C, Buggle F, Ruf A. Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. Stroke. 2003;34:849-854.
23. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331-337.
24. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of athero-thrombotic events. N Engl J Med. 2006;354:1706-1717.
25. Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376:1233-1243.
26. Serebruany VL, Malinin AI, Sane DC, Jilma B, Takserman A, Atar D, et al. Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. Eur J Pharmacol. 2004;499: 315-324.